<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> in neutropenic children is a major cause of morbidity and mortality in children treated for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In developing countries, children with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> are often malnourished at diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>In Blantyre, Malawi, children with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are treated with a local protocol with limited toxicity </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this study was to evaluate the incidence and outcome of febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> during this treatment and the association with <z:hpo ids='HP_0004395'>malnutrition</z:hpo> at diagnosis </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We documented nutritional status, febrile and/or neutropenic episodes, antibiotic therapy and short term outcome of <z:hpo ids='HP_0000001'>all</z:hpo> children with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treated according to the local protocol and admitted from January 2007 to March 2008 </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Fifty eight (69%) of 84 patients were acutely malnourished at diagnosis with an arm muscle area (AMA) below the 5(th) percentile </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0004395'>Malnutrition</z:hpo> at diagnosis was associated with a significantly higher rate of profound <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>This association remained significant (OR 12; 95% C.I </plain></SENT>
<SENT sid="8" pm="."><plain>1.5 - infinitely; P = 0.012) after control for clinical stage of <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">disease, bone marrow</z:e> involvement and <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> which are possible confounders </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with profound <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, prolonged <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and treatment related <z:hpo ids='HP_0011420'>deaths</z:hpo> were malnourished at diagnosis </plain></SENT>
<SENT sid="10" pm="."><plain>Four (4.9%) of 81 patients died of treatment related causes; three of them due to a <z:mp ids='MP_0001795'>Gram negative</z:mp> <z:e sem="disease" ids="C0036690" disease_type="Disease or Syndrome" abbrv="">septicaemia</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: <z:hpo ids='HP_0011009'>Acute</z:hpo> <z:hpo ids='HP_0004395'>malnutrition</z:hpo> at diagnosis is associated with significantly more treatment related profound <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>The intensity of chemotherapeutic regimens has to be adapted to the level of available supportive care and patients' nutritional status and tolerance to avoid unacceptable morbidity and mortality </plain></SENT>
<SENT sid="13" pm="."><plain>This local treatment protocol for Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> has a treatment related mortality of 5% in patients in Malawi </plain></SENT>
</text></document>